Vertex Pharmaceuticals

At Vertex, we are focused on progressive and often-overlooked kidney conditions with limited treatment options like IgA nephropathy (IgAN) and APOL1-mediated kidney disease (AMKD). Using our proven model of serial innovation, we're targeting the root cause of disease to address persistent unmet need.

There is significant unmet need across the renal disease landscape. At Vertex, we are focused on transforming the treatment of serious kidney diseases through our unique approach to innovation. Our work spans IgA nephropathy (IgAN), primary membranous nephropathy (pMN), APOL1-mediated kidney disease (AMKD), and autosomal dominant polycystic kidney disease (ADPKD), areas where we hope to make a meaningful difference for patients.

At Vertex, our goal is to redefine the future of kidney disease treatment. Our team continues to push boundaries and advance science with the goal of potentially bringing hope to patients and families impacted by serious conditions like IgA nephropathy (IgAN).

Progress across our nephrology programs continues to reinforce our belief in what may be possible for patients living with serious kidney diseases. Guided by deep scientific expertise and a history of serial innovation, we are focused on advancing therapies that have the potential to meaningfully change the treatment landscape for people living with serious kidney diseases.

Sickle cell disease (SCD) is a life-shortening disease that can affect every part of the body, leading to long-term complications for those living with the disease. At Vertex, we’re committed to making a difference. Learn more about our work in sickle cell disease.

Pain crises are the hallmark symptom of sickle cell disease (SCD). They can happen at anytime and anywhere in the body, usually requiring urgent medical care. Better understanding of SCD is key to supporting those living with this serious disease. At Vertex, we’re committed to having a transformative impact for people living with SCD.